Compare RLGT & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLGT | MDWD |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.6M | 238.5M |
| IPO Year | N/A | 2014 |
| Metric | RLGT | MDWD |
|---|---|---|
| Price | $6.64 | $16.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.00 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 140.2K | 103.9K |
| Earning Date | 02-09-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.35 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $925,786,000.00 | $20,932,000.00 |
| Revenue This Year | $3.77 | $15.89 |
| Revenue Next Year | $3.51 | $25.33 |
| P/E Ratio | $21.36 | ★ N/A |
| Revenue Growth | ★ 16.42 | 6.15 |
| 52 Week Low | $5.44 | $14.14 |
| 52 Week High | $7.94 | $22.51 |
| Indicator | RLGT | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 34.52 |
| Support Level | $6.66 | $16.32 |
| Resistance Level | $6.79 | $19.70 |
| Average True Range (ATR) | 0.15 | 0.78 |
| MACD | 0.01 | -0.26 |
| Stochastic Oscillator | 80.39 | 2.46 |
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.